Russell Investments Group Ltd. decreased its holdings in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 43.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 260,687 shares of the company's stock after selling 197,990 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.12% of QIAGEN worth $10,407,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of QIAGEN during the 4th quarter worth approximately $202,000. Wells Fargo & Company MN raised its stake in QIAGEN by 31.8% during the 4th quarter. Wells Fargo & Company MN now owns 66,779 shares of the company's stock worth $2,974,000 after acquiring an additional 16,106 shares in the last quarter. GAMMA Investing LLC lifted its position in QIAGEN by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after acquiring an additional 1,425 shares during the last quarter. Cetera Investment Advisers lifted its position in QIAGEN by 23.2% in the first quarter. Cetera Investment Advisers now owns 13,917 shares of the company's stock valued at $551,000 after acquiring an additional 2,620 shares during the last quarter. Finally, LPL Financial LLC boosted its stake in QIAGEN by 2.6% in the fourth quarter. LPL Financial LLC now owns 17,240 shares of the company's stock valued at $768,000 after acquiring an additional 432 shares in the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of analysts have recently commented on the company. Wall Street Zen cut QIAGEN from a "strong-buy" rating to a "buy" rating in a research report on Monday, August 11th. UBS Group lifted their price target on QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Barclays began coverage on QIAGEN in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price objective for the company. Cowen restated a "hold" rating on shares of QIAGEN in a research report on Thursday, August 7th. Finally, Robert W. Baird upped their price target on shares of QIAGEN from $42.00 to $43.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Eight analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, QIAGEN has an average rating of "Hold" and an average target price of $49.69.
Check Out Our Latest Stock Report on QIAGEN
QIAGEN Stock Down 1.4%
Shares of QIAGEN stock opened at $48.66 on Tuesday. The company has a market cap of $10.82 billion, a P/E ratio of 28.75, a PEG ratio of 2.59 and a beta of 0.64. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. QIAGEN N.V. has a one year low of $37.63 and a one year high of $51.88. The firm has a fifty day moving average of $48.42 and a two-hundred day moving average of $43.74.
QIAGEN (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The firm had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. During the same period in the prior year, the company posted $0.55 earnings per share. The firm's revenue for the quarter was up 7.7% on a year-over-year basis. On average, analysts forecast that QIAGEN N.V. will post 2.26 earnings per share for the current year.
QIAGEN Announces Dividend
The firm also recently announced a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were issued a $0.25 dividend. The ex-dividend date of this dividend was Wednesday, July 2nd. This represents a yield of 52.0%. QIAGEN's dividend payout ratio (DPR) is 14.79%.
About QIAGEN
(
Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
See Also
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QIAGEN N.V. (NYSE:QGEN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider QIAGEN, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and QIAGEN wasn't on the list.
While QIAGEN currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access